Copyright
©The Author(s) 2015.
World J Hepatol. Jun 28, 2015; 7(12): 1632-1651
Published online Jun 28, 2015. doi: 10.4254/wjh.v7.i12.1632
Published online Jun 28, 2015. doi: 10.4254/wjh.v7.i12.1632
Indication | Randomised studies |
Adjuvant | Sorafenib vs placebo |
Intermediate HCC | Chemoembolisation ± sorafenib |
Chemoembolisation ± brivanib | |
Chemoembolisation ± everolimus | |
Advanced HCC | |
First line | Sorafenib ± erlotinib |
Sorafenib vs brivanib | |
Sorafenib vs sunitinib | |
Sorafenib vs linifanib | |
Sorafenib ± yttrium-90 | |
Sorafenib ± doxorubicin | |
Second line | Brivanib vs placebo |
Everolimus vs placebo | |
Ramucirmab vs placebo |
- Citation: Attwa MH, El-Etreby SA. Guide for diagnosis and treatment of hepatocellular carcinoma. World J Hepatol 2015; 7(12): 1632-1651
- URL: https://www.wjgnet.com/1948-5182/full/v7/i12/1632.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i12.1632